Retatrutide vs CagriSema compares a triple agonist with an amylin-plus-GLP-1 combo, covering trial results, dosing, side effects, and safety.
Retatrutide and CagriSema are two of the most closely watched investigational weight-loss drugs, and neither one is approved by the FDA. Retatrutide is Eli Lilly's single-molecule triple agonist that activates the GLP-1, GIP, and glucagon receptors, while CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. There has been no head-to-head clinical trial comparing the two, so every comparison today comes from separate studies with different designs, doses, and durations.
That gap explains why retatrutide vs cagrisema searches rarely end with a clean answer. Both drugs produce large weight reductions in their own trials, and the real differences lie in mechanism, dosing, data maturity, and side effect profiles.
How Retatrutide Works
Retatrutide is a triple hormone receptor agonist, meaning one molecule hits three receptors at once:
- GLP-1 slows gastric emptying and reduces appetite.
- GIP affects insulin secretion and may influence fat metabolism.
- Glucagon raises energy expenditure, which is the feature that separates retatrutide from older GLP-1 drugs.
Because it is a single peptide, retatrutide is dosed as one weekly subcutaneous injection. The Phase 2 trial tested doses from 1 mg to 12 mg per week using stepwise escalation to limit gastrointestinal side effects.
How CagriSema Works
CagriSema combines two separate molecules in one injection. Cagrilintide is a long-acting amylin analog, and amylin is a hormone released alongside insulin that promotes fullness and slows stomach emptying. Semaglutide adds GLP-1 receptor agonism on top of that signal.
The investigational Phase 3 dose is 2.4 mg cagrilintide plus 2.4 mg semaglutide, injected once weekly. Anyone comparing cagrilintide vs retatrutide is really comparing two appetite pathways: amylin plus GLP-1 versus GLP-1, GIP, and glucagon together.
CagriSema is not FDA-approved for weight management or any other indication, although Novo Nordisk has reported Phase 3 results and said it plans to pursue regulatory filings.
Retatrutide vs CagriSema: Side-by-Side Comparison
| Feature | Retatrutide | CagriSema |
|---|---|---|
| Developer | Eli Lilly | Novo Nordisk |
| Mechanism | Triple agonist: GLP-1, GIP, glucagon | Amylin analog plus GLP-1 agonist |
| Formulation | One molecule | Two molecules in a fixed-dose combination |
| Dose studied | 1 mg to 12 mg weekly (Phase 2) | 2.4 mg / 2.4 mg weekly (Phase 3) |
| Route | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Phase 2 weight loss | About 24.2% at 48 weeks (12 mg) | About 15.6% at 32 weeks (2.4/2.4 mg) |
| Phase 3 weight loss | TRIUMPH program ongoing | About 22.7% at 68 weeks in REDEFINE 1, on-treatment analysis |
| FDA status | Not approved | Not approved |
Weight Loss Results: What the Trials Show
Retatrutide's Phase 2 results, published in the New England Journal of Medicine in 2023, showed roughly 24.2% mean weight loss at 48 weeks with the 12 mg dose in adults with obesity who did not have diabetes. Lower doses produced smaller reductions, and side effects scaled with dose as well.
CagriSema's Phase 2 trial reported about 15.6% weight loss at 32 weeks with the 2.4 mg/2.4 mg dose. In the larger Phase 3 REDEFINE 1 trial, average weight loss reached about 22.7% at 68 weeks in the on-treatment analysis, with a lower figure when everyone randomized was counted.
These numbers are not directly comparable. Retatrutide's headline result comes from a shorter Phase 2 study, while CagriSema's comes from a longer Phase 3 study that enrolled thousands of participants. Longer trials tend to show larger weight loss, and Phase 3 populations usually include more people who struggle to stay on treatment.
Key takeaway: There is no head-to-head trial comparing retatrutide and CagriSema, so no one can claim that one drug is more effective than the other.
The same logic applies to approved medications. People searching for retatrutide vs tirzepatide which is better are asking a question that also has no direct trial answer, because retatrutide remains investigational while tirzepatide is approved for both type 2 diabetes and weight management.
Side Effects and Tolerability
Both drugs share the gastrointestinal side effect profile that is typical of incretin-based therapies. The most commonly reported events in their trials were:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Reduced appetite
Retatrutide's Phase 2 data also showed dose-dependent increases in resting heart rate and reports of paresthesia, or unusual tingling sensations under the skin, which researchers flagged for monitoring. CagriSema trials reported injection-site reactions and mostly mild to moderate GI events, concentrated during dose escalation.
Lean mass loss is a shared concern for every drug in this class. Estimates from body-composition studies suggest that roughly 20% to 40% of total weight lost may come from lean tissue, which is why discussions of retatrutide muscle loss vs tirzepatide stay so active among researchers and clinicians.
Anyone considering either drug should talk with a healthcare professional about personal risks, especially with a history of pancreatitis, gallbladder disease, thyroid cancer, or kidney problems.
The Broader Weight Loss Pipeline
Retatrutide and CagriSema are only two entries in a crowded pipeline. Some debates, like survodutide vs retatrutide, pit a dual GLP-1 and glucagon agonist against the triple agonist. Others, such as aod 9604 vs retatrutide, compare a growth hormone fragment with a completely different mechanism to an incretin-based drug.
What all of these compounds share is that human data is still limited, and approved products remain the only options available outside a clinical trial.
Bottom Line
Both retatrutide and CagriSema produced weight loss larger than what approved single and dual agonists achieved in their own trials, but neither is FDA-approved and neither can be legally prescribed for weight loss today.
CagriSema is further along in development, with completed Phase 3 obesity trials and a stated intent to file for approval. Retatrutide is still working through its Phase 3 TRIUMPH program, so its final efficacy and safety profile is not yet known.
For now, the choice between them is largely theoretical. A direct comparison will only be possible if a head-to-head trial is ever run.
Frequently Asked Questions
Is retatrutide better than CagriSema for weight loss?
No head-to-head trial has compared the two drugs, so there is no reliable way to rank one above the other. In separate studies, retatrutide produced about 24.2% weight loss at 48 weeks at the 12 mg dose, while CagriSema produced about 22.7% at 68 weeks in an on-treatment Phase 3 analysis. Those trials used different designs, doses, and durations, so the numbers should not be compared directly.
What is the difference between retatrutide and CagriSema?
Retatrutide is a single molecule that activates the GLP-1, GIP, and glucagon receptors. CagriSema is a combination of two molecules: cagrilintide, an amylin analog, and semaglutide, a GLP-1 agonist. Both are given as weekly subcutaneous injections, and neither is FDA-approved for any use.
When will retatrutide or CagriSema be available in the US?
Neither drug has a confirmed approval date. CagriSema has completed Phase 3 obesity trials and Novo Nordisk has said it plans to seek approval, while retatrutide is still being studied in its Phase 3 TRIUMPH program. Until the FDA approves either drug, they are only available to participants in clinical trials.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.